Affection Animal Pharmaceuticals
Animal vaccine R&D company
panaceacapital.comCrawled Nov 9, 2026
Animal vaccine R&D company
The company develops innovative life support medical devices.
Novel base editor to push the limits of gene editing
Discovering and developing FIC/BIC therapeutics
Developing novel cancer immunotherapy
Panacea Capital has invested in over 30 life sciences companies in therapeutics, medical devices, and diagnostics across the United States and Asia.
Brain tumors pose a serious challenge due to their complexity.
China’s Order No. 818 outlines requirements for foreign biotech companies working with Innovation Investment Treaties (IITs) in cell and gene therapy.
Actym Therapeutics appointed Steven Vicik, PhD, as Chief Technical Officer to advance its solid tumor drug development.
Actym Therapeutics raised $25.5 million in Series A funding, bringing its total to $59.5 million, to advance ACTM-838 into clinical trials and its STACT platform.
The first-in-human trial of ACTM-838 will assess its safety, tolerability, and efficacy in treating solid tumors by delivering IL-15 and STING payloads.
Actym Therapeutics named Thomas Smart as Chief Executive Officer to lead its solid tumor drug development.
Actym Therapeutics appointed Mary J. Janatpour, PhD, as Chief Scientific Officer and Shouryadeep Srivastava, MD, PhD, as Senior Vice President of Clinical Development.
Latest news and insights from Panacea Capital and its life sciences portfolio companies, including therapeutics, diagnostics and medical device updates.
Panacea Capital’s investment team includes partners with over 100 years of combined biotech experience.
Spun out of Kleiner Perkins, Panacea Capital is a global life sciences venture fund with 30+ portfolio companies across the US and Asia.
Panacea Capital's investment model spans incubation, Global/Asia asset acceleration and public investing in therapeutics, medical devices and diagnostics.
Panacea Capital is a global life sciences venture fund investing in therapeutics, medical devices and diagnostics — from incubation to public markets.